EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to eight new employees under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan.

Rhea-AI Summary

EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to eight new employees under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan.

The options cover up to 158,100 shares at an exercise price of $12.35, with a ten-year term and four-year vesting.

Argus May 18 session

-5.26% close to close Open Argus

Details

News Market Reaction – EYPT

On May 18, the day this news came out, EYPT closed 5.26% below the previous close.

Data tracked by StockTitan Argus for the May 18 session.

Key Figures

Inducement options: 158,100 shares New employees: 8 employees Exercise price: $12.35 per share +3 more

Inducement options

158,100 shares

Aggregate non-statutory stock options granted to new employees

New employees

8 employees

Recipients of inducement stock option grants

Exercise price

$12.35 per share

Option strike price, matching May 15, 2026 closing price

Option term

10 years

Contractual life of inducement stock options

Vesting period

4 years

25% at first anniversary, then monthly over following three years

Initial vesting tranche

25%

Portion of options vesting on first anniversary of grant date

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   Phase 3 DSMC update

   24h Move

   -1.4%

   Third positive DSMC recommendation for DURAVYU Phase 3 wet AMD trials.

2. May 06

   Q1 2026 earnings

   24h Move

   -2.9%

   Q1 2026 results with higher operating spend and ongoing Phase 3 programs.

3. Apr 29

   Earnings date notice

   24h Move

   -4.5%

   Announcement of date and webcast details for Q1 2026 results.

4. Apr 16

   Inducement option grants

   24h Move

   +0.8%

   Inducement options for fourteen new employees under NASDAQ Rule 5635(c)(4).

5. Mar 16

   Inducement option grants

   24h Move

   +1.6%

   Inducement options for six new employees under NASDAQ Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, NASDAQ Listing Rule 5635(c)(4), exercise price, vest

4 terms

non-statutory stock options financial

"the Company granted non-statutory stock options to new employees as inducement awards"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

NASDAQ Listing Rule 5635(c)(4) regulatory

"as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The option awards have an exercise price of $12.35 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The options have a ten-year term and vest over four years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 158,100 shares of EyePoint common stock to eight new employees. The stock options were granted on May 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $12.35 per share, the closing price of EyePoint’s common stock on May 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media:
Helen O’Gorman
FTI Consulting
helen.ogorman@fticonsulting.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did EyePoint (EYPT) grant on May 15, 2026?

EyePoint granted non-statutory stock options to buy up to 158,100 common shares to eight new employees. According to EyePoint, these inducement awards were approved by the Compensation Committee and granted outside the 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).

What is the exercise price and term of the new EyePoint (EYPT) inducement stock options?

The inducement stock options have an exercise price of $12.35 per share and a ten-year term. According to EyePoint, the exercise price equals the closing price of its common stock on May 15, 2026, the date on which the options were granted.

How do the EyePoint (EYPT) inducement options granted in May 2026 vest over time?

The options vest over four years, with 25% vesting on the first anniversary of each employee’s grant date. According to EyePoint, the remaining shares vest in equal monthly installments over the next three years, subject to continued service through each vesting date.

Why did EyePoint (EYPT) issue inducement stock options under NASDAQ Listing Rule 5635(c)(4)?

EyePoint issued the options as inducement awards material to each new employee entering employment with the company. According to EyePoint, these grants were made outside the 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

How many employees received EyePoint (EYPT) inducement stock options and how many shares are covered?

Eight new employees received inducement stock option awards covering up to an aggregate of 158,100 EyePoint common shares. According to EyePoint, these options were granted on May 15, 2026, following approval by the company’s Compensation Committee.

What conditions must be met for EyePoint (EYPT) employees to fully vest in the inducement options?

Employees must remain in service with EyePoint through each applicable vesting date to receive the options. According to EyePoint, vesting is conditioned on continued employment during the four-year vesting schedule, including the one-year cliff and subsequent monthly vesting installments.